New antibody drugs for advanced HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests two new antibody-based drugs (trastuzumab rezetecan and trastuzumab deruxtecan) designed to treat advanced breast cancer that has spread or cannot be removed with surgery. These drugs target HER2, a protein found on certain cancer cells, and may help patients whose cancer has progressed after previous treatment with trastuzumab and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be confirmed HER2-positive (a specific protein marker) and either unresectable or have spread to other parts of your body
- You must have previously received trastuzumab and taxane chemotherapy for advanced cancer, or your cancer came back within 12 months of finishing earlier treatment
- Your cancer must have grown or progressed on your most recent treatment, confirmed by imaging
- Your heart function must be normal (ejection fraction ≥50%), and your blood and organ function must meet specific healthy thresholds
- You cannot have untreated spinal cord compression or active brain metastases, unless already treated and stable for at least 1 month
- You must be able to wait at least 4 weeks since your last cancer treatment before starting this trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
This trial tests a sequence of targeted therapy drugs for HER2-positive advanced breast cancer that has spread or cannot be removed by surgery. It aims to see if starting with trastuzumab rezetecan, followed by pyrotinib and trastuzumab plus capecitabine, helps control the cancer.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
This trial tests a new targeted drug called trastuzumab rezetecan (T-DXh) for patients with HER2-positive breast cancer who didn't have a complete response to standard chemotherapy and targeted drugs. The goal is to see if this new drug can help shrink remaining cancer.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.